Multiple Myeloma | Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Multiple Myeloma (Companion Faculty Lecture)
Research To Practice | Oncology Videos · Dr. Neil Love
May 24, 202429m 5s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring a slide presentation and related discussion from Dr Joshua Richter, including the following topics:
- Similarities and differences between the cellular targets and mechanisms of action of BCMA- and non-BCMA-directed bispecific antibodies for multiple myeloma (MM) (0:00)
- Antitumor activity observed with teclistamab and elranatamab for relapsed/refractory MM (3:46)
- Published findings with investigational anti-BCMA bispecific antibodies such as linvoseltamab and alnuctamab for pretreated MM (12:40)
- Efficacy and safety of approved and investigational non-BCMA-targeted bispecific antibodies in patients with heavily pretreated MM (16:26)
- Early data with bispecific antibodies in combination with other systemic therapies for MM (22:55)
- Spectrum, incidence, severity and timing of cytokine release syndrome, neurotoxicity and other adverse events with BCMA- and non-BCMA-targeted bispecific antibodies (26:39)